Asia Pacific Carbapenem-Based Antibiotics Market
Historic Data:    |   Base Year: 2023   |   Forecast Period: 2024-2031
Forecast to 2028 - COVID-19 Impact and Regional Analysis By Type (Meropenem, Doripenem, Imipenem, Tebipenem, and Others), Indication (Bacterial Meningitis, Acute Pelvic Infections, Respiratory Tract Infections, Intra-Abdominal Infections, Urinary Tract Infections, and Others), and Distribution Channel (Retail Pharmacies, Online Pharmacies, and Hospital Pharmacies)

No. of Pages: 152    |    Report Code: TIPRE00028784    |    Category: Life Sciences

Available Report Formats

pdf-format excel-format pptx-format
Request Free Sample Buy Now
Asia Pacific Carbapenem-Based Antibiotics Market

1. Introduction

1.1 Business Market Insights Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Market Insights
2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research
3.2 Primary Research
  • 3.2.1 Hypothesis formulation:
  • 3.2.2 Macro-economic factor analysis:
  • 3.2.3 Developing base number:
  • 3.2.4 Data Triangulation:
  • 3.2.5 Country level data:

4. Asia Pacific Carbapenem-Based Antibiotics Market Landscape

4.1 Market Overview
4.2 Porter's Five Forces Analysis
  • 4.2.1 Bargaining Power of Suppliers
  • 4.2.2 Bargaining Power of Buyers
  • 4.2.3 Threat of New Entrants
  • 4.2.4 Competitive Rivalry
  • 4.2.5 Threat of Substitutes
4.3 Ecosystem Analysis
  • 4.3.1 Raw Material Suppliers
  • 4.3.2 Manufacturers
  • 4.3.3 Distributors/Suppliers
  • 4.3.4 End Users

5. Asia Pacific Carbapenem-Based Antibiotics Market – Key Market Dynamics

5.1 Growth Drivers
  • 5.1.1
  • 5.1.2 Rising prevalence of bacterial infections
  • 5.1.3 Increased demand for last-resort antibiotics
  • 5.1.4 Growth in hospital-acquired infections
5.2 Market Opportunities
  • 5.2.1
  • 5.2.2 Development of novel carbapenem derivatives
  • 5.2.3 Demand in emerging markets healthcare
  • 5.2.4 Expansion in injectable antibiotic formats
5.3 Future Trends
  • 5.3.1
  • 5.3.2 Focus on antibiotic stewardship programs
  • 5.3.3 Increased research on resistant pathogens
  • 5.3.4 Development of combination therapies
5.4 Impact of Drivers and Restraints

6. Asia Pacific Carbapenem-Based Antibiotics Market Regional Analysis

6.1 Asia Pacific Carbapenem-Based Antibiotics Market Overview
6.2 Asia Pacific Carbapenem-Based Antibiotics Market Revenue 2019-2028 (US$ Million)
6.3 Asia Pacific Carbapenem-Based Antibiotics Market Forecast Analysis

7. Asia Pacific Carbapenem-Based Antibiotics Market Analysis – by Type

7.1 Meropenem
  • 7.1.1 Overview
  • 7.1.2 Meropenem: Asia Pacific Carbapenem-Based Antibiotics Market – Revenue and Forecast to 2031 (US$ Million)
7.2 Doripenem
  • 7.2.1 Overview
  • 7.2.2 Doripenem: Asia Pacific Carbapenem-Based Antibiotics Market – Revenue and Forecast to 2031 (US$ Million)
7.3 Imipenem
  • 7.3.1 Overview
  • 7.3.2 Imipenem: Asia Pacific Carbapenem-Based Antibiotics Market – Revenue and Forecast to 2031 (US$ Million)
7.4 Tebipenem
  • 7.4.1 Overview
  • 7.4.2 Tebipenem: Asia Pacific Carbapenem-Based Antibiotics Market – Revenue and Forecast to 2031 (US$ Million)

8. Asia Pacific Carbapenem-Based Antibiotics Market Analysis – by Indication

8.1 Bacterial Meningitis
  • 8.1.1 Overview
  • 8.1.2 Bacterial Meningitis: Asia Pacific Carbapenem-Based Antibiotics Market – Revenue and Forecast to 2028 (US$ Million)
8.2 Acute Pelvic Infections
  • 8.2.1 Overview
  • 8.2.2 Acute Pelvic Infections: Asia Pacific Carbapenem-Based Antibiotics Market – Revenue and Forecast to 2028 (US$ Million)
8.3 Respiratory Tract Infections
  • 8.3.1 Overview
  • 8.3.2 Respiratory Tract Infections: Asia Pacific Carbapenem-Based Antibiotics Market – Revenue and Forecast to 2028 (US$ Million)
8.4 Intra-Abdominal Infections
  • 8.4.1 Overview
  • 8.4.2 Intra-Abdominal Infections: Asia Pacific Carbapenem-Based Antibiotics Market – Revenue and Forecast to 2028 (US$ Million)
8.5 Urinary Tract Infections
  • 8.5.1 Overview
  • 8.5.2 Urinary Tract Infections: Asia Pacific Carbapenem-Based Antibiotics Market – Revenue and Forecast to 2028 (US$ Million)

9. Asia Pacific Carbapenem-Based Antibiotics Market Analysis – by Distribution Channel

9.1 Retail Pharmacies
  • 9.1.1 Overview
  • 9.1.2 Urinary Tract Infections: Asia Pacific Carbapenem-Based Antibiotics Market – Revenue and Forecast to 2028 (US$ Million)
9.2 Online Pharmacies
  • 9.2.1 Overview
  • 9.2.2 Urinary Tract Infections: Asia Pacific Carbapenem-Based Antibiotics Market – Revenue and Forecast to 2028 (US$ Million)
9.3 Hospital Pharmacies
  • 9.3.1 Overview
  • 9.3.2 Urinary Tract Infections: Asia Pacific Carbapenem-Based Antibiotics Market – Revenue and Forecast to 2028 (US$ Million)

10. Asia Pacific Carbapenem-Based Antibiotics Market – Asia-Pacific Analysis

10.1 Asia-Pacific
  • 10.1.1 Asia Pacific Carbapenem-Based Antibiotics Market Breakdown, by Key Country, 2022 and 2028 (%)
  • 10.1.1.1 Asia Pacific Carbapenem-Based Antibiotics Market – Revenue and Forecast Analysis – by Country
  • 10.1.1.1 China: Asia Pacific Carbapenem-Based Antibiotics Market – Revenue and Forecast to 2028 (US$ Million)
    • 10.1.1.1.1 China: Asia Pacific Carbapenem-Based Antibiotics Market Breakdown, by Type
    • 10.1.1.1.2 China: Asia Pacific Carbapenem-Based Antibiotics Market Breakdown, by Indication
    • 10.1.1.1.3 China: Asia Pacific Carbapenem-Based Antibiotics Market Breakdown, by Distribution Channel
  • 10.1.1.2 India: Asia Pacific Carbapenem-Based Antibiotics Market – Revenue and Forecast to 2028 (US$ Million)
    • 10.1.1.2.1 India: Asia Pacific Carbapenem-Based Antibiotics Market Breakdown, by Type
    • 10.1.1.2.2 India: Asia Pacific Carbapenem-Based Antibiotics Market Breakdown, by Indication
    • 10.1.1.2.3 India: Asia Pacific Carbapenem-Based Antibiotics Market Breakdown, by Distribution Channel
  • 10.1.1.3 Japan: Asia Pacific Carbapenem-Based Antibiotics Market – Revenue and Forecast to 2028 (US$ Million)
    • 10.1.1.3.1 Japan: Asia Pacific Carbapenem-Based Antibiotics Market Breakdown, by Type
    • 10.1.1.3.2 Japan: Asia Pacific Carbapenem-Based Antibiotics Market Breakdown, by Indication
    • 10.1.1.3.3 Japan: Asia Pacific Carbapenem-Based Antibiotics Market Breakdown, by Distribution Channel
  • 10.1.1.4 Australia: Asia Pacific Carbapenem-Based Antibiotics Market – Revenue and Forecast to 2028 (US$ Million)
    • 10.1.1.4.1 Australia: Asia Pacific Carbapenem-Based Antibiotics Market Breakdown, by Type
    • 10.1.1.4.2 Australia: Asia Pacific Carbapenem-Based Antibiotics Market Breakdown, by Indication
    • 10.1.1.4.3 Australia: Asia Pacific Carbapenem-Based Antibiotics Market Breakdown, by Distribution Channel
  • 10.1.1.5 Rest of Asia-Pacific : Asia Pacific Carbapenem-Based Antibiotics Market – Revenue and Forecast to 2028 (US$ Million)
    • 10.1.1.5.1 Rest of Asia-Pacific : Asia Pacific Carbapenem-Based Antibiotics Market Breakdown, by Type
    • 10.1.1.5.2 Rest of Asia-Pacific : Asia Pacific Carbapenem-Based Antibiotics Market Breakdown, by Indication
    • 10.1.1.5.3 Rest of Asia-Pacific : Asia Pacific Carbapenem-Based Antibiotics Market Breakdown, by Distribution Channel

11. Competitive Landscape

11.1 Heat Map Analysis
11.2 Company Positioning and Concentration

12. Asia Pacific Carbapenem-Based Antibiotics Market Industry Landscape

12.1 Overview
12.2 Mergers and Acquisitions
12.3 Agreements, Collaborations, and Joint Ventures
12.4 New Product Launches
12.5 Expansions and Other Strategic Developments

13. Company Profiles

13.1 ACS Dobfar S.p.A
  • 13.1.1 Key Facts
  • 13.1.2 Business Description
  • 13.1.3 Products and Services
  • 13.1.4 Financial Overview
  • 13.1.5 SWOT Analysis
  • 13.1.6 Key Developments
13.2 Iterum Therapeutics plc
  • 13.2.1 Key Facts
  • 13.2.2 Business Description
  • 13.2.3 Products and Services
  • 13.2.4 Financial Overview
  • 13.2.5 SWOT Analysis
  • 13.2.6 Key Developments
13.3 DAEWOONG PHARMACEUTICAL CO., LTD
  • 13.3.1 Key Facts
  • 13.3.2 Business Description
  • 13.3.3 Products and Services
  • 13.3.4 Financial Overview
  • 13.3.5 SWOT Analysis
  • 13.3.6 Key Developments
13.4 Aurobindo Pharma Ltd
  • 13.4.1 Key Facts
  • 13.4.2 Business Description
  • 13.4.3 Products and Services
  • 13.4.4 Financial Overview
  • 13.4.5 SWOT Analysis
  • 13.4.6 Key Developments
13.5 Gland Pharma Limited
  • 13.5.1 Key Facts
  • 13.5.2 Business Description
  • 13.5.3 Products and Services
  • 13.5.4 Financial Overview
  • 13.5.5 SWOT Analysis
  • 13.5.6 Key Developments
13.6 Merck & Co., Inc.
  • 13.6.1 Key Facts
  • 13.6.2 Business Description
  • 13.6.3 Products and Services
  • 13.6.4 Financial Overview
  • 13.6.5 SWOT Analysis
  • 13.6.6 Key Developments
13.7 Sumitomo Dainippon Pharma Co., Ltd.
  • 13.7.1 Key Facts
  • 13.7.2 Business Description
  • 13.7.3 Products and Services
  • 13.7.4 Financial Overview
  • 13.7.5 SWOT Analysis
  • 13.7.6 Key Developments
13.8 Savior Lifetec
  • 13.8.1 Key Facts
  • 13.8.2 Business Description
  • 13.8.3 Products and Services
  • 13.8.4 Financial Overview
  • 13.8.5 SWOT Analysis
  • 13.8.6 Key Developments
13.9 Pfizer Inc.
  • 13.9.1 Key Facts
  • 13.9.2 Business Description
  • 13.9.3 Products and Services
  • 13.9.4 Financial Overview
  • 13.9.5 SWOT Analysis
  • 13.9.6 Key Developments
13.10 Spero Therapeutics
  • 13.10.1 Key Facts
  • 13.10.2 Business Description
  • 13.10.3 Products and Services
  • 13.10.4 Financial Overview
  • 13.10.5 SWOT Analysis
  • 13.10.6 Key Developments

14. Appendix

14.1 About Business Market Insights

The List of Companies - Asia Pacific Carbapenem-Based Antibiotics Market

  1. ACS Dobfar S.p.A
  2. Iterum Therapeutics plc
  3. DAEWOONG PHARMACEUTICAL CO., LTD
  4. Aurobindo Pharma Ltd
  5. Gland Pharma Limited
  6. Merck & Co., Inc.
  7. Sumitomo Dainippon Pharma Co., Ltd.
  8. Savior Lifetec
  9. Pfizer Inc.
  10. Spero Therapeutics